Metabolic / Weight Loss · 5mg × 10 vials
In plain terms: Cagrilintide is a weight-loss compound - injectable, long-acting and well studied.
Cagrilintide is a long-acting injectable analog of amylin, the pancreatic hormone co-released with insulin after a meal. Native amylin tells the brain "you're full" by binding amylin receptors in the area postrema of the hindbrain (a region outside the blood-brain barrier that gates satiety and nausea signals). Cagrilintide is engineered to mimic this but with two key changes: it's non-fibrillating (native amylin clumps and aggregates, which is why pramlintide had to be dosed three times a day with every meal), and it's albumin-bound for a ~7-8 day half-life that supports once-weekly dosing. It activates the AMY1, AMY2, AMY3 receptor subtypes (calcitonin receptor + RAMP1/2/3 complexes) and also the bare calcitonin receptor directly, which is why it has some downstream effects on bone and calcium handling that pramlintide does not.
The reason cagrilintide stacks cleanly with every GLP-1 in the catalog is that the amylin pathway is genuinely separate from GLP-1R, GIPR, and the glucagon receptor. Mechanistically the effects compound additively: cagrilintide slows gastric emptying by 40-50%, suppresses postprandial glucagon, and adds satiety through the homeostatic AND hedonic (reward) brain circuits, while GLP-1s (sema, tirz, reta) work primarily through hypothalamic appetite suppression and peripheral metabolic effects. Two non-overlapping satiety circuits = roughly additive weight loss. In the REDEFINE 1 Phase 3 trial, CagriSema (cagri + sema combo) hit 20.4% body weight loss at 68 weeks vs 16.1% for sema alone and 11.8% for cagri alone, confirming the synergy at scale. Preclinical body composition data also shows cagrilintide preserves lean mass while preferentially burning fat, which is the muscle-sparing advantage that endocrinologists keep highlighting vs pure GLP-1s.
Typical dose ranges by experience level - educational reference. Message us and we tailor it to you.
Almost no one runs cagri as a standalone first peptide - it's almost always added on top of an existing GLP-1. "Beginner" here really means "first time on cagri specifically," not first time on a metabolic peptide. If layering onto an already-stable GLP-1 (sema/tirz/reta), hold the GLP-1 dose steady while titrating cagri. If the GLP-1 is also in titration, only step one drug at a time, otherwise you can't tell which one is causing GI sides. 5 mg vial at 0.25 mg/wk = ~20 weeks of research, plenty of runway.
2.4 mg/wk is the dose that almost every customer ends up at when stacked. Cagri at this band also softens GLP-1 nausea for some users - not the textbook expectation (amylin technically signals through the same nausea-gating area postrema), but the community signal is consistent: stable cagri makes the GLP-1 step-up easier than running it solo. The mechanism is probably that splitting satiety across two non-overlapping circuits means you don't need to push the GLP-1 as hard.
Advanced use is monotherapy cagri at 4.5 mg/wk OR cagri 2.4 mg stacked with reta/tirz at top dose. The first is rare in real-world use (everyone wants the GLP-1 backbone), the second is the standard "stack peptide" pattern. After hitting target weight, taper to a 1.2 mg/wk maintenance dose alongside whatever GLP-1 maintenance is being run.
Straight talk - what people actually report, and what the studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
, NEJM 2025](https://www.nejm.org/doi/full/10.1056/NEJMoa2502081) - Phase 3, n=3,417, 68 weeks, CagriSema 20.4% vs sema 16.1% vs cagri 11.8% vs placebo 2.3%
Read study ↗PubMedCagrilintide lowers bodyweight through brain amylin receptors 1 and 3, PMC12270663 (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12270663/) - receptor pharmacology, AMY1R/AMY3R dependency, area postrema mechanism, fat-mass-preferential weight loss
Read study ↗PubMedEfficacy and Safety of Cagrilintide and CagriSema vs Semaglutide - systematic review/meta-analysis, PMID 41834765 (2025)](https://pubmed.ncbi.nlm.nih.gov/41834765/) - pooled efficacy and AE rates across trials
Read study ↗PubMedCagrilintide: A Long-Acting Amylin Analog for Obesity, Cardiology in Review 2024Lau Phase 2 monotherapy dose-finding (0.3-4.5 mg), pharmacokinetics, mechanism
Read study ↗PubMedAmylin as a Future Obesity Treatment, PMC8735818class background, amylin pharmacology
Read study ↗PubMedAmylin Revisited: 5-Year Perspective on Diabesity, PMC12884623 (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12884623/) - updated class review
Read study ↗Aggregated sentiment from public forums & socials - real-world reports, not individual endorsements.
Nausea: lighter than reta/tirz at equivalent loss rates, most users describe as "manageable bloat + slight queasiness" not full GI shutdown
Injection-site reactions: most-reported community complaint. Persistent red welts at injection sites if not rotated aggressively. Some users describe a small lump that takes a week to fade.
Fatigue: less commonly flagged than with reta - cagri's "blah" period during titration is shorter (1-2 weeks per step vs 3-4 on reta)
Reduced food reward: users describe food becoming "less interesting" rather than "I'm not hungry" - closer to hedonic suppression than pure appetite cut. Some describe this as preferable to GLP-1 food aversion.
- Divergence: clinical trials describe satiety in homeostatic terms (eat less); community reports describe a hedonic shift (cravings for sweets/junk drop more than baseline hunger). Mechanistic data from PMC12270663 supports the community read - cagri does hit hedonic reward circuits via the AP/NTS/LPBN pathway.
Sulfur burps: less common than on sema
Route: SubQ
Injection site: abdomen, outer thigh, or upper arm. Rotate every injection, don't reuse the same spot within 7 days (injection-site redness is the most reported AE after nausea and persistent re-use lipodystrophy is a real signal in trial data)
Storage: refrigerated, 28 days after reconstitution; unreconstituted vials refrigerated, sealed
Notes: Same-day-each-week injection (long half-life means it doesn't matter morning vs evening but consistency helps tracking). Don't shake the vial, swirl gently. Most users inject cagri on the same day as their GLP-1 stack partner using a separate syringe at a separate site (don't mix in the same syringe - different pH/stability profiles). No fasting requirement.